December 3, 2020
Business News

Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

CAMBRIDGE, Mass.–()–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. These early data demonstrate proof of mechanism in patients with advanced solid tumors and establish a maximum tolerated dose (MTD) for continuous daily dosing. The data are being presented in a poster session at the 32nd EORTC-NCI-AACR Symposium.

“These early findings from our Phase 1…

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Humana’s Medicaid Membership to Grow with iCare Acquisition in Wisconsin
RenaissanceRe Names Shannon Lowry Bender as Group General Counsel
DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit